CA2687979C - Sustained delivery formulations of risperidone compounds - Google Patents
Sustained delivery formulations of risperidone compounds Download PDFInfo
- Publication number
- CA2687979C CA2687979C CA2687979A CA2687979A CA2687979C CA 2687979 C CA2687979 C CA 2687979C CA 2687979 A CA2687979 A CA 2687979A CA 2687979 A CA2687979 A CA 2687979A CA 2687979 C CA2687979 C CA 2687979C
- Authority
- CA
- Canada
- Prior art keywords
- risperidone
- day
- flowable composition
- plgh
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 945
- 239000000203 mixture Substances 0.000 title claims abstract description 486
- 238000009472 formulation Methods 0.000 title claims description 280
- 230000002459 sustained effect Effects 0.000 title description 12
- 229960001534 risperidone Drugs 0.000 claims abstract description 877
- 239000007943 implant Substances 0.000 claims abstract description 225
- 230000009969 flowable effect Effects 0.000 claims abstract description 151
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 10
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 206010010219 Compulsions Diseases 0.000 claims abstract description 8
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims abstract description 8
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 8
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 8
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 8
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 8
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 564
- 239000003814 drug Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 65
- 239000002904 solvent Substances 0.000 claims description 44
- 229920001577 copolymer Polymers 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 42
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 238000011065 in-situ storage Methods 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 15
- 238000013270 controlled release Methods 0.000 claims description 14
- 150000002009 diols Chemical class 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 abstract description 143
- 239000002207 metabolite Substances 0.000 abstract description 120
- 229940002612 prodrug Drugs 0.000 abstract description 115
- 239000000651 prodrug Substances 0.000 abstract description 115
- 229920001169 thermoplastic Polymers 0.000 abstract description 112
- 238000013268 sustained release Methods 0.000 abstract description 60
- 239000012730 sustained-release form Substances 0.000 abstract description 60
- 239000007787 solid Substances 0.000 abstract description 46
- 229920000642 polymer Polymers 0.000 description 216
- 238000012360 testing method Methods 0.000 description 167
- 241000282472 Canis lupus familiaris Species 0.000 description 150
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 143
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 128
- 229940079593 drug Drugs 0.000 description 89
- 230000036470 plasma concentration Effects 0.000 description 77
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 76
- 229920000747 poly(lactic acid) Polymers 0.000 description 72
- 238000002347 injection Methods 0.000 description 59
- 239000007924 injection Substances 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- -1 esteramide groups Chemical group 0.000 description 51
- 229920000728 polyester Polymers 0.000 description 50
- 239000010839 body fluid Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 49
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 48
- 210000001124 body fluid Anatomy 0.000 description 47
- 241000700159 Rattus Species 0.000 description 41
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 40
- 229940116333 ethyl lactate Drugs 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
- 239000000463 material Substances 0.000 description 34
- 239000000499 gel Substances 0.000 description 30
- 239000000178 monomer Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 239000011159 matrix material Substances 0.000 description 29
- 239000000126 substance Substances 0.000 description 29
- 229940106887 risperdal Drugs 0.000 description 28
- 239000003607 modifier Substances 0.000 description 26
- 239000004416 thermosoftening plastic Substances 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- 206010047700 Vomiting Diseases 0.000 description 22
- 241000283973 Oryctolagus cuniculus Species 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 20
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 20
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 19
- 229960004046 apomorphine Drugs 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000004310 lactic acid Substances 0.000 description 19
- 235000014655 lactic acid Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 239000000654 additive Substances 0.000 description 18
- 239000012736 aqueous medium Substances 0.000 description 17
- 238000011068 loading method Methods 0.000 description 17
- 230000003285 pharmacodynamic effect Effects 0.000 description 17
- 230000003474 anti-emetic effect Effects 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 16
- 150000003077 polyols Chemical class 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 229920005862 polyol Polymers 0.000 description 15
- 239000011148 porous material Substances 0.000 description 15
- 239000004014 plasticizer Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 11
- 206010040880 Skin irritation Diseases 0.000 description 10
- 150000001298 alcohols Chemical class 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 235000013773 glyceryl triacetate Nutrition 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 10
- 230000036556 skin irritation Effects 0.000 description 10
- 231100000475 skin irritation Toxicity 0.000 description 10
- 229960002622 triacetin Drugs 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000001087 glyceryl triacetate Substances 0.000 description 9
- 239000001069 triethyl citrate Substances 0.000 description 9
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 9
- 235000013769 triethyl citrate Nutrition 0.000 description 9
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229920001897 terpolymer Polymers 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 7
- 229920002988 biodegradable polymer Polymers 0.000 description 7
- 239000004621 biodegradable polymer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 7
- 238000013139 quantization Methods 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- 229920000954 Polyglycolide Polymers 0.000 description 6
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 239000003880 polar aprotic solvent Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
- 208000034656 Contusions Diseases 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 101100074998 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-2 gene Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000008512 biological response Effects 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 229920001519 homopolymer Polymers 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000003301 hydrolyzing effect Effects 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 238000007433 macroscopic evaluation Methods 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 4
- OMIHCBSQSYMFDP-UHFFFAOYSA-N 3-hydroxy-5-methoxy-3-methoxycarbonyl-5-oxopentanoic acid Chemical compound COC(=O)CC(O)(CC(O)=O)C(=O)OC OMIHCBSQSYMFDP-UHFFFAOYSA-N 0.000 description 4
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 239000012867 bioactive agent Substances 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 210000000476 body water Anatomy 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001991 dicarboxylic acids Chemical class 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229940074076 glycerol formal Drugs 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 3
- UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 description 3
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000005233 alkylalcohol group Chemical group 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 150000008064 anhydrides Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229920006158 high molecular weight polymer Polymers 0.000 description 3
- 150000001261 hydroxy acids Chemical class 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 150000003628 tricarboxylic acids Chemical class 0.000 description 3
- 150000004072 triols Chemical class 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 2
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 2
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
- 229930188620 butyrolactone Natural products 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000005587 carbonate group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- QVQUOSCLJISGOB-UHFFFAOYSA-N deca-1,3-dien-5-one Chemical compound CCCCCC(=O)C=CC=C QVQUOSCLJISGOB-UHFFFAOYSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 238000012429 release testing Methods 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17beta-estradiol Natural products OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FMKIFJLNOGNQJR-UHFFFAOYSA-N 2,3-dihydroxypropyl tridec-2-enoate Chemical compound CCCCCCCCCCC=CC(=O)OCC(O)CO FMKIFJLNOGNQJR-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- XASWYPVFCVEQSU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XASWYPVFCVEQSU-UHFFFAOYSA-N 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 1
- YNOXCRMFGMSKIJ-UHFFFAOYSA-N 2-methylcitric acid Chemical compound OC(=O)C(C)C(O)(C(O)=O)CC(O)=O YNOXCRMFGMSKIJ-UHFFFAOYSA-N 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 101100074988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-1 gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002932 anti-schizophrenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000008430 aromatic amides Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229940118398 atridox Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical compound OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940055390 glycerin / propylene glycol Drugs 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- SWYVHBPXKKDGLL-UHFFFAOYSA-N n,n,3-trimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C)=C1 SWYVHBPXKKDGLL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- LNIQEBQSPWOLPH-UHFFFAOYSA-N naphthalene-1-carboxylic acid Chemical compound OC(=O)c1cccc2ccccc12.OC(=O)c1cccc2ccccc12 LNIQEBQSPWOLPH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- NZEVKZAEMSMLMC-UHFFFAOYSA-N nmp-7 Chemical compound C=1C=C2N(CCCCC)C3=CC=CC=C3C2=CC=1C(=O)N1CCCCC1 NZEVKZAEMSMLMC-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-WKUFJEKOSA-N oestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920001855 polyketal Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94034007P | 2007-05-25 | 2007-05-25 | |
| US60/940,340 | 2007-05-25 | ||
| PCT/US2008/001928 WO2008153611A2 (en) | 2007-05-25 | 2008-02-13 | Sustained delivery formulations of risperidone compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2687979A1 CA2687979A1 (en) | 2008-12-18 |
| CA2687979C true CA2687979C (en) | 2017-07-04 |
Family
ID=39496214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2687979A Active CA2687979C (en) | 2007-05-25 | 2008-02-13 | Sustained delivery formulations of risperidone compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10010612B2 (enExample) |
| EP (2) | EP2907524A1 (enExample) |
| JP (3) | JP2010531807A (enExample) |
| CN (1) | CN101801415B (enExample) |
| AU (1) | AU2008262545B2 (enExample) |
| BR (1) | BRPI0811319A2 (enExample) |
| CA (1) | CA2687979C (enExample) |
| ES (1) | ES2562878T3 (enExample) |
| MX (2) | MX354603B (enExample) |
| NZ (2) | NZ597621A (enExample) |
| WO (1) | WO2008153611A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| WO2008153611A2 (en) | 2007-05-25 | 2008-12-18 | Qlt Usa, Inc. | Sustained delivery formulations of risperidone compounds |
| CN101653422B (zh) * | 2008-08-20 | 2013-03-20 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
| CN101584652B (zh) * | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| PL2394664T3 (pl) * | 2010-05-31 | 2016-12-30 | Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu | |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| PL2394663T3 (pl) * | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| CN103384528B (zh) * | 2010-11-24 | 2016-04-13 | 杜雷科特公司 | 生物可降解的药物递送组合物 |
| CN102058517A (zh) * | 2010-12-31 | 2011-05-18 | 泰州万全医药科技有限公司 | 一种帕潘立酮缓释剂及其制备方法 |
| ES2607497T3 (es) | 2011-04-25 | 2017-03-31 | Shandong Luye Pharmaceutical Co., Ltd. | Composición de risperidona de microesferas de liberación controlada |
| RS62059B1 (sr) | 2011-05-31 | 2021-07-30 | Laboratorios Farmaceuticos Rovi S A | Kompozicija implanta risperidona i/ili paliperidona |
| PT2529757E (pt) * | 2011-05-31 | 2014-02-27 | Rovi Lab Farmaceut Sa | Formulação para implante de paliperidona |
| DE102013011399A1 (de) | 2012-07-31 | 2014-02-06 | Amw Gmbh | Implantat mit Risperidon |
| EP2900220B1 (en) * | 2012-09-28 | 2018-12-12 | Delpor, Inc. | Device and methods for sustained release of antipsychotic medications |
| US9737605B2 (en) | 2013-03-11 | 2017-08-22 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| CN106573015B (zh) | 2014-06-11 | 2021-11-26 | 麻省理工学院 | 肠溶弹性体 |
| ES2808150T3 (es) | 2014-11-07 | 2021-02-25 | Indivior Uk Ltd | Regímenes de dosificación de buprenorfina |
| CN104398474A (zh) * | 2014-11-21 | 2015-03-11 | 内蒙古医科大学附属医院 | 一种利培酮鼻用凝胶剂及其制备方法 |
| CN107592803B (zh) | 2015-05-01 | 2021-01-22 | 麻省理工学院 | 可触发形状记忆感应装置 |
| MX2018003380A (es) | 2015-09-21 | 2018-08-16 | Teva Pharmaceuticals Int Gmbh | Formulaciones de olanzapina de liberacion sostenida. |
| US20190015415A1 (en) * | 2015-09-30 | 2019-01-17 | Indivior Uk Limited | Methods for treating schizophrenia |
| JP7085473B2 (ja) | 2015-10-23 | 2022-06-16 | リンドラ セラピューティクス， インコーポレイティド | 治療薬の持続放出用の胃内滞留システム及びその使用方法 |
| AU2016355236C1 (en) | 2015-11-16 | 2022-09-22 | Medincell | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| ES2963058T3 (es) | 2015-12-08 | 2024-03-25 | Lyndra Therapeutics Inc | Configuraciones geométricas para sistemas de residencia gástrica |
| US20170196802A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long Acting Injectable Formulations |
| US12109305B2 (en) | 2016-05-27 | 2024-10-08 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| EP3518902A4 (en) | 2016-09-30 | 2020-07-08 | Lyndra, Inc. | GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES |
| CA3048499A1 (en) * | 2017-01-04 | 2018-07-12 | Pharmathen S.A. | Process for preparing biodegradable polymers of high molecular weight |
| WO2018151849A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| US12023406B2 (en) | 2017-06-09 | 2024-07-02 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| US11083678B2 (en) * | 2017-09-20 | 2021-08-10 | Kao Corporation | Hair dyeing method |
| US20190117573A1 (en) * | 2017-10-19 | 2019-04-25 | Hyalo Technologies, LLC | Composition and method of preparation of risperidone extended release preparation |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| WO2019226516A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| MX2020012459A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| US20210386745A1 (en) * | 2019-01-22 | 2021-12-16 | Indivior Uk Limited | Methods for treating schizophrenia |
| BR112022004535A2 (pt) | 2019-09-13 | 2022-06-07 | Medincell S A | Formulações de entrega de fármaco |
| CA3159716A1 (en) * | 2019-12-05 | 2021-06-10 | Fresenius Kabi Usa, Llc | Method for analyzing degarelix and associated products |
| JP2023509463A (ja) * | 2020-01-03 | 2023-03-08 | プリボ テクノロジーズ，インコーポレイティド | 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物 |
| EP4221688A1 (en) * | 2020-09-30 | 2023-08-09 | Tolmar International Limited | Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients |
| WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| CN113267579B (zh) * | 2021-05-18 | 2022-08-30 | 中南民族大学 | 一种监测利培酮血药浓度的方法 |
| KR20240117521A (ko) | 2021-07-06 | 2024-08-01 | 마크 하슬레톤 | 세로토닌 재흡수 억제제 금단 증후군의 치료 |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| WO2023233051A1 (es) | 2022-05-18 | 2023-12-07 | Laboratorios Farmacéuticos Rovi, S.A. | Composiciones inyectables de liberación prolongada para su uso en el tratamiento con risperidona junto a inhibidores de la enzima cyp2d6 |
| TW202523334A (zh) * | 2023-12-13 | 2025-06-16 | 大陸商長春金賽藥業有限責任公司 | 原位皮下植入的女性激素調節組合物及其製備方法和用途 |
| CN119950530B (zh) * | 2025-01-24 | 2025-12-05 | 山东新时代药业有限公司 | 一种包含他莫昔芬与人参皂苷的纳米乳及其制备方法 |
Family Cites Families (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB806876A (en) | 1956-02-16 | 1959-01-07 | Wellcome Found | Improvements in and relating to disposable hypodermic injection devices |
| GB873526A (en) | 1957-08-14 | 1961-07-26 | Upjohn Co | Fluid compositions comprising (acetyl-salicylic acid)-anhydride |
| GB887872A (en) | 1958-06-25 | 1962-01-24 | Upjohn Co | Improvements in or relating to pharmaceutical preparations |
| DE1467938C3 (de) | 1964-05-22 | 1973-12-20 | F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) | Wasserdispergierbares Arzneipräparat für Tiere |
| JPS5078634A (enExample) | 1973-11-16 | 1975-06-26 | ||
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
| US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
| US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| US4534974A (en) | 1984-07-31 | 1985-08-13 | Carter-Wallace, Inc. | Pharmaceutical compositions with codeine |
| US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| GB8522453D0 (en) | 1985-09-11 | 1985-10-16 | Lilly Industries Ltd | Chewable capsules |
| JPS62298530A (ja) | 1986-06-16 | 1987-12-25 | Otsuka Pharmaceut Co Ltd | 坐薬用医薬組成物 |
| IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| DE3927113C2 (de) | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung |
| US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
| US5558880A (en) | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
| US5660851A (en) | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
| AU7880991A (en) | 1990-05-10 | 1991-11-27 | Novo Nordisk A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| JPH0456736U (enExample) | 1990-09-14 | 1992-05-15 | ||
| US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
| ATE183639T1 (de) | 1991-02-18 | 1999-09-15 | Commw Scient Ind Res Org | Zusammensetzung zur verwendung in der transdermalen verabreichung |
| JP3145742B2 (ja) | 1991-09-19 | 2001-03-12 | 日東電工株式会社 | ゴム系感圧性接着剤とその接着シ―ト |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| WO1993023019A1 (en) | 1992-05-11 | 1993-11-25 | Sri International | Transdermal drug delivery systems and related compositions and methods of use |
| DK0669128T3 (da) | 1992-11-17 | 2000-06-19 | Yoshitomi Pharmaceutical | Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme |
| TW376319B (en) | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| JP2651106B2 (ja) | 1993-06-28 | 1997-09-10 | 大同鋼板株式会社 | 金属屋根材の葺設構造及びその葺設方法 |
| NZ260909A (en) | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
| US5643605A (en) | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| ATE212830T1 (de) | 1993-11-19 | 2002-02-15 | Alkermes Inc | Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel |
| SK282231B6 (sk) | 1993-11-19 | 2001-12-03 | Janssen Pharmaceutica N. V. | Farmaceutický prostriedok na liečenie psychotických porúch |
| CA2582666C (en) * | 1994-04-08 | 2010-05-25 | Qlt Usa, Inc. | Controlled release implant |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| AU4652596A (en) | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
| JP3274579B2 (ja) | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | 脳血管障害に伴う精神症候治療剤 |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| JP4330175B2 (ja) | 1995-06-07 | 2009-09-16 | デュレクト コーポレイション | 高粘度液体による制御された送達系 |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6004969A (en) | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
| EP1210942B1 (en) | 1996-05-07 | 2007-03-21 | Alkermes, Inc. | Microparticles |
| US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| JP4346696B2 (ja) | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | 経皮治療用装置 |
| ES2172793T3 (es) | 1996-06-17 | 2002-10-01 | Janssen Pharmaceutica Nv | Formas de dosificacion biconvexas de desintegracion rapida. |
| IL130532A0 (en) | 1996-12-20 | 2000-06-01 | Alza Corp | Gel composition and methods |
| DE19701912C1 (de) | 1997-01-10 | 1998-05-14 | Jenapharm Gmbh | Injizierbares Implantat |
| US5948787A (en) | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
| IT1292396B1 (it) | 1997-06-23 | 1999-02-08 | Lisapharma Spa | Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni |
| US6622036B1 (en) | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| JP4205231B2 (ja) | 1998-02-10 | 2009-01-07 | ゼネラル・エレクトリック・カンパニイ | バーナ |
| US6733767B2 (en) | 1998-03-19 | 2004-05-11 | Merck & Co., Inc. | Liquid polymeric compositions for controlled release of bioactive substances |
| US7208011B2 (en) | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
| US6261583B1 (en) * | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
| US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| DE19923551A1 (de) | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE10190041D2 (de) | 2000-01-11 | 2002-12-05 | Roland Bodmeier | Implantate, Partikel |
| KR100393478B1 (ko) | 2000-03-29 | 2003-08-06 | 주식회사종근당 | 자가유화 매트릭스형 경점막·경피흡수제제 |
| EP1280804B1 (en) | 2000-05-05 | 2004-04-14 | RPG Life Sciences Limited | A process for the preparation of anti-psychotic 3- 2- 4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido 1,2,-a]pyrimidin-4-one |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| WO2002000137A1 (en) | 2000-06-28 | 2002-01-03 | Shukla Atul J | Biodegradable vehicles and delivery systems of biologically active substances |
| DE10035889A1 (de) | 2000-07-24 | 2002-02-14 | Lohmann Therapie Syst Lts | Medizinischer Haftkleber mit einem Gehalt an Zucker-Estern |
| WO2002014286A1 (en) | 2000-08-14 | 2002-02-21 | Teva Pharmaceutical Industries Ltd. | Preparation of risperidone |
| DE10044545A1 (de) | 2000-09-05 | 2002-04-04 | Roland Bodmeier | Retardpartikeldispersion |
| IT250575Y1 (it) | 2000-10-10 | 2003-09-24 | Gimatic Spa | Sistema di guida registrabile per griffe di pinze azionate da unfluido |
| WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| WO2002067895A2 (en) | 2000-11-16 | 2002-09-06 | Durect Corporation | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
| JP4724354B2 (ja) | 2001-02-23 | 2011-07-13 | ジェネンテック， インコーポレイテッド | 注射用の崩壊性ポリマー |
| US20040018238A1 (en) | 2001-02-26 | 2004-01-29 | Shukla Atul J | Biodegradable vehicles and delivery systems of biolgically active substances |
| EP1379197A4 (en) | 2001-03-23 | 2009-06-03 | Durect Corp | DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM |
| US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
| GB0112324D0 (en) | 2001-05-21 | 2001-07-11 | Croda Int Plc | Compounds |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| JP2003063954A (ja) | 2001-08-24 | 2003-03-05 | Saitama Daiichi Seiyaku Kk | リザーバー型貼付剤 |
| CN1703197A (zh) | 2001-11-14 | 2005-11-30 | 阿尔扎有限公司 | 可注射的长效组合物和其使用 |
| JP5170935B2 (ja) | 2001-11-14 | 2013-03-27 | デュレクト コーポレーション | 注入可能なデポー組成物 |
| NZ533436A (en) | 2001-11-14 | 2007-10-26 | Alza Corp | Catheter injectable depot compositons and uses thereof |
| US20040258731A1 (en) | 2001-11-21 | 2004-12-23 | Tsuyoshi Shimoboji | Preparation approriate for cartilage tissue formation |
| AU2003227827B2 (en) | 2002-03-12 | 2008-09-25 | Ethypharm | Composition having gelling properties for the prolonged delivery of bioactive substances |
| US7041320B1 (en) | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| MY139059A (en) | 2002-06-24 | 2009-08-28 | Alza Corp | Reusable, spring driven autoinjector |
| AR039729A1 (es) | 2002-06-25 | 2005-03-09 | Alza Corp | Formulaciones de deposito de corta duracion |
| US20040003401A1 (en) | 2002-06-27 | 2004-01-01 | Koninklijke Philips Electronics N.V. | Method and apparatus for using cluster compactness as a measure for generation of additional clusters for stereotyping programs |
| CN1684663A (zh) | 2002-07-31 | 2005-10-19 | 阿尔萨公司 | 可注射的多模式聚合物储库组合物以及其用途 |
| US7097634B2 (en) | 2002-07-31 | 2006-08-29 | Alza Corporation | Injection device providing automatic needle retraction |
| WO2004020439A2 (en) | 2002-08-30 | 2004-03-11 | Sunil Sadanand Nadkarni | Improved process for preparation of risperidone |
| CA2500908A1 (en) | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| KR20040034996A (ko) | 2002-10-18 | 2004-04-29 | 한미약품 주식회사 | 리스페리돈의 개선된 제조방법 |
| EP1575616A2 (en) | 2002-10-25 | 2005-09-21 | Pfizer Products Inc. | Novel injectable depot formulations |
| DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| PL377333A1 (pl) | 2002-11-06 | 2006-01-23 | Alza Corporation | Preparaty depot o kontrolowanym uwalnianiu |
| EP2959893A1 (en) | 2002-12-13 | 2015-12-30 | DURECT Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
| WO2004071491A1 (en) | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| EP1615924A1 (en) | 2003-04-22 | 2006-01-18 | Synthon B.V. | Water soluble salts of risperidone |
| KR20060023140A (ko) | 2003-05-30 | 2006-03-13 | 알자 코포레이션 | 이식성 탄성중합체 데포 조성물, 이의 용도 및 이의제조방법 |
| CN101862455A (zh) | 2003-06-26 | 2010-10-20 | 普西维达公司 | 原位胶凝的药物递送系统 |
| TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| FI20045223L (fi) | 2004-06-15 | 2005-12-16 | Bioretec Oy | Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20050032781A1 (en) * | 2003-08-06 | 2005-02-10 | Elliot Ehrich | Methods for administering active agents to CYP 2D6 sensitive patients |
| CA2546482A1 (en) | 2003-09-01 | 2005-03-10 | F H Faulding & Co Limited | Compositions and methods for delivery of biologically active agents |
| WO2005037949A2 (en) | 2003-10-07 | 2005-04-28 | Chrysalis Technologies Incorporated | Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
| US20050106214A1 (en) | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20050281879A1 (en) | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| EP1689465A4 (en) | 2003-12-05 | 2011-10-12 | Zogenix Inc | DEVICE FOR DELIVERY OF A NEEDLELESS INJECTOR USED FOR DRUG DELIVERY |
| EP1711159B1 (en) | 2003-12-30 | 2013-03-20 | Durect Corporation | Solid implants containing a block copolymer for controlled release of a gnrh compound |
| US8329203B2 (en) | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| EP2633853A1 (en) | 2004-01-12 | 2013-09-04 | The Trustees of The University of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| WO2005089670A1 (en) | 2004-03-15 | 2005-09-29 | Durect Corporation | Pharmaceutical compositions for administration to a sinus |
| IS7290A (is) | 2004-05-28 | 2005-11-29 | Actavis Group | Lyfjasamsetningar sem innihalda risperidone |
| DE602005008247D1 (de) | 2004-06-04 | 2008-08-28 | Camurus Ab | Flüssige depotformulierungen |
| EP1604693A1 (en) | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| CN101146523B (zh) | 2004-10-21 | 2010-12-29 | 杜雷科特公司 | 透皮给药系统 |
| RS53890B1 (sr) | 2004-11-10 | 2015-08-31 | Tolmar Therapeutics, Inc. | Stabilizovan polimerni sistem za isporuku |
| GB2420976B (en) | 2004-11-19 | 2006-12-20 | Zvi Finkelstein | Therapeutic implant |
| AR052155A1 (es) | 2004-12-14 | 2007-03-07 | Novartis Ag | Compuestos organicos |
| US20090092650A1 (en) | 2004-12-15 | 2009-04-09 | Warren Stephen L | Sustained Delivery Formulations of Octreotide Compounds |
| EP1830900A1 (en) | 2004-12-16 | 2007-09-12 | Miv Therapeutics Inc. | Multi-layer drug delivery device and method of manufacturing same |
| US9415034B2 (en) | 2005-01-05 | 2016-08-16 | National Defense Medical Center | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
| US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| CN103637977A (zh) | 2005-07-18 | 2014-03-19 | 宾夕法尼亚大学理事会 | 含药植入物及其使用方法 |
| US20070020186A1 (en) | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
| EP1912627B1 (en) | 2005-08-11 | 2016-08-10 | Promedon S.A. | Composition comprising polymeric, water-insoluble, anionic particles, processes and uses |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| CA2627292C (en) | 2005-10-26 | 2012-04-17 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system |
| RU2427383C2 (ru) | 2006-01-18 | 2011-08-27 | КьюПиЭс, ЭлЭлСи | Фармацевтические композиции с повышенной стабильностью |
| US20090022798A1 (en) | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| WO2008038185A2 (en) | 2006-09-25 | 2008-04-03 | Koninklijke Philips Electronics N.V. | Hot water kettle comprising an acoustic member for generating an acoustic signal |
| AU2007304425B2 (en) | 2006-10-02 | 2013-12-05 | Spepharma Ag | Non-mucoadhesive film dosage forms |
| KR20090087441A (ko) | 2006-10-05 | 2009-08-17 | 파나세아 바이오테크 리미티드 | 새로운 형태의 주입형 데포 조성물 및 이를 위한 조제방법 |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| SI2079767T1 (sl) | 2006-10-11 | 2015-01-30 | Tolmar Therapeutics, Inc. | Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo |
| GB0620661D0 (en) | 2006-10-18 | 2006-11-29 | Pharmasol Ltd | Novel compounds |
| ES2550014T3 (es) | 2007-02-15 | 2015-11-03 | Tolmar Therapeutics, Inc. | Poli-(lactida/glicolida) de descarga lenta y métodos para producir polímeros |
| KR101521989B1 (ko) | 2007-03-02 | 2015-05-28 | 테이카 세이야쿠 가부시키가이샤 | 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제 |
| WO2008124013A1 (en) | 2007-04-03 | 2008-10-16 | Trimeris, Inc. | Novel formulations for delivery of antiviral peptide therapeutics |
| AU2008254538B2 (en) | 2007-05-18 | 2013-11-07 | Durect Corporation | Improved depot formulations |
| WO2008153611A2 (en) | 2007-05-25 | 2008-12-18 | Qlt Usa, Inc. | Sustained delivery formulations of risperidone compounds |
| MX2010002409A (es) | 2007-09-03 | 2010-05-19 | Nanotherapeutics Inc | Composiciones y metodos para la distribucion de farmacos escasamente solubles. |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| EP2219622A1 (en) | 2007-12-06 | 2010-08-25 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| FR2926996B1 (fr) | 2008-01-31 | 2013-06-21 | Ethypharm Sa | Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine |
| US8586103B2 (en) | 2008-02-08 | 2013-11-19 | Foresee Pharmaceuticals, Llc | Non-polymeric compositions for controlled drug delivery |
| AU2009212367B2 (en) | 2008-02-08 | 2013-08-01 | Foresee Pharmaceuticals Co., Ltd. | Composition for sustained release delivery of proteins or peptides |
| JP5286850B2 (ja) | 2008-03-14 | 2013-09-11 | 大日本印刷株式会社 | 液体用紙容器用包装材料およびその包装材料から製造される液体用紙容器 |
| WO2009120889A2 (en) | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| EP2291174B1 (en) | 2008-06-03 | 2015-01-28 | Tolmar Therapeutics, Inc. | Flowable composition comprising biocompatible oligomer-polymer compositions |
| US8877225B2 (en) | 2008-06-03 | 2014-11-04 | Tolmar Therapeutics, Inc. | Controlled release copolymer formulation with improved release kinetics |
| US8114429B2 (en) | 2008-09-15 | 2012-02-14 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| US8257722B2 (en) | 2008-09-15 | 2012-09-04 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| US8128951B2 (en) | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| MY167918A (en) | 2009-04-23 | 2018-09-27 | Londonpharma Ltd | Composition for use in the sublingual delivery of medicaments to humans |
| KR101752014B1 (ko) | 2009-05-01 | 2017-06-28 | 아데어 파마슈티컬스 인코포레이티드 | 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물 |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| FR2949061B1 (fr) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
| CA2780779C (en) | 2009-11-18 | 2020-02-04 | Nektar Therapeutics | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
| US20130023553A1 (en) | 2010-01-12 | 2013-01-24 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
| US20130210751A1 (en) | 2010-03-15 | 2013-08-15 | Ipsen Pharma, S.A.S. | Pharmaceutical Compositions of Growth Hormone Secretagogue Receptor Ligands |
| US20110230816A1 (en) | 2010-03-18 | 2011-09-22 | Tyco Healthcare Group Lp | Gels for Transdermal Delivery |
| PL2394664T3 (pl) | 2010-05-31 | 2016-12-30 | Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu | |
| PL2394663T3 (pl) | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| EP2585092A1 (en) | 2010-06-24 | 2013-05-01 | Torrent Pharmaceuticals Limited | Pharmaceutical composition containing goserelin for in-situ implant |
| EP2619212B1 (en) | 2010-09-21 | 2016-01-06 | Purdue Pharma L.P. | Buprenorphine analogs as opioid receptor agonists and/or antagonists |
| ES2528650T3 (es) | 2010-11-17 | 2015-02-11 | Hexal Ag | Sistema terapéutico transdérmico que comprende buprenorfina |
| CN103384528B (zh) | 2010-11-24 | 2016-04-13 | 杜雷科特公司 | 生物可降解的药物递送组合物 |
| EP2643020A4 (en) | 2010-11-26 | 2014-11-12 | Univ Witwatersrand Jhb | ACTIVE RELEASE DEVICE |
| RS62059B1 (sr) | 2011-05-31 | 2021-07-30 | Laboratorios Farmaceuticos Rovi S A | Kompozicija implanta risperidona i/ili paliperidona |
| SG10201604754VA (en) | 2011-12-12 | 2016-08-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
| US9468599B2 (en) | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| US20140134261A1 (en) | 2012-08-21 | 2014-05-15 | Trinity Laboratories, Inc. | Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores |
| RU2513514C1 (ru) | 2012-11-23 | 2014-04-20 | Общество с ограниченной ответственностью "НПК "Трифарма" | Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции |
| CN103142458B (zh) | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | 无成瘾性镇痛缓释递药系统的组方与制备方法 |
| US9737605B2 (en) | 2013-03-11 | 2017-08-22 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| IN2013MU03658A (enExample) | 2013-11-21 | 2015-09-25 | Akanksha Bindeshwari Prasad Yadav | |
| US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
-
2008
- 2008-02-13 WO PCT/US2008/001928 patent/WO2008153611A2/en not_active Ceased
- 2008-02-13 MX MX2013002428A patent/MX354603B/es unknown
- 2008-02-13 ES ES08725543.6T patent/ES2562878T3/es active Active
- 2008-02-13 NZ NZ59762108A patent/NZ597621A/xx not_active IP Right Cessation
- 2008-02-13 CA CA2687979A patent/CA2687979C/en active Active
- 2008-02-13 EP EP15000500.7A patent/EP2907524A1/en not_active Ceased
- 2008-02-13 JP JP2010509326A patent/JP2010531807A/ja active Pending
- 2008-02-13 AU AU2008262545A patent/AU2008262545B2/en not_active Ceased
- 2008-02-13 MX MX2009012781A patent/MX337286B/es active IP Right Grant
- 2008-02-13 EP EP08725543.6A patent/EP2152315B1/en active Active
- 2008-02-13 US US12/602,058 patent/US10010612B2/en active Active
- 2008-02-13 BR BRPI0811319 patent/BRPI0811319A2/pt not_active Application Discontinuation
- 2008-02-13 NZ NZ581862A patent/NZ581862A/en not_active IP Right Cessation
- 2008-02-13 CN CN200880100394.0A patent/CN101801415B/zh not_active Expired - Fee Related
-
2013
- 2013-04-18 JP JP2013087247A patent/JP5795606B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-18 US US14/490,082 patent/US9186413B2/en active Active
- 2014-09-18 US US14/490,034 patent/US9180197B2/en active Active
- 2014-09-25 JP JP2014194758A patent/JP2014240436A/ja not_active Withdrawn
-
2017
- 2017-12-29 US US15/858,525 patent/US10376590B2/en active Active
-
2019
- 2019-07-11 US US16/509,287 patent/US11013809B2/en active Active
-
2021
- 2021-04-22 US US17/237,207 patent/US11712475B2/en active Active
-
2022
- 2022-12-19 US US18/083,774 patent/US20230135427A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11712475B2 (en) | Sustained delivery formulations of risperidone compound | |
| EP3360538B1 (en) | Injectable flowable composition comprising buprenorphine | |
| US10592168B1 (en) | Injectable flowable composition comprising buprenorphine | |
| US20130203796A1 (en) | Injectable flowable composition comprising buprenorphine | |
| HK40097172A (en) | Injectable flowable composition comprising buprenorphine | |
| HK1143731B (en) | Sustained delivery formulations of risperidone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130208 |